BRIEF

on Envista (NASDAQ:NVST)

DEXIS Debuts IS ScanFlow v.1.0.10 to Revolutionize Dental Implant Procedures with AI

DEXIS, a leader in dental imaging, has unveiled DEXIS™IS ScanFlow v.1.0.10, an innovative update for its intraoral scanning software designed to optimize dental implant workflows through guided processes and artificial intelligence enhancements. Released on March 19, 2024, this software aims to streamline the entire implant process from diagnosis to delivery, promising increased productivity for dental professionals.

Brian Gooch, VP of Marketing at DEXIS, emphasized the benefits of the new update in making scanning operations fast and easy, especially in complex situations. The integration with the DEXIS Imaging Suite software enhances digital impression data accuracy, crucial for implant case planning and sharing with labs or colleagues.

Early feedback from adopters such as Dr. Sebastian Patzelt highlights the software's effectiveness in digitalizing oral tissues for various dental cases. IS ScanFlow's new AI Matching tool and enhancements to the Implant Scan Body AI Assist feature improve data capture in challenging scenarios, offering a high level of precision and reducing manual effort in the workflow.

The software introduces the Full Arch Implant workflow for simplified data capture and automatic scan alignment. Additionally, efficient lab communications are enabled through real-time updates and collaboration features within the Patient History screen. Gooch also noted the synergy between IS ScanFlow and DTX Studio™ Clinic, which together, form a comprehensive implant workflow solution.

As part of DEXIS's commitment to enhancing dental care practices, IS ScanFlow v.1.0.10 is poised to set a new benchmark in dental digital diagnostics and treatment planning.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Envista news